References

Cancer statistics, 2022

2022 · External reference

Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance

10.1016/j.drup.2012.01.008 · 2012 · External reference

Novel indazole skeleton derivatives containing 1,2,3-triazole as potential anti-prostate cancer drugs

10.1016/j.bmcl.2022.128654 · 2022 · External reference

Synthesis and antitumor activity of novel 5- and 6-substituted indazole derivatives

10.6023/cjoc202107049 · 2022 · External reference

Cancer statistics for the year 2020: an overview

10.1002/ijc.33588 · 2021 · External reference

Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions

10.1093/annonc/mdy102 · 2018 · External reference

Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

10.18632/oncotarget.8934 · 2016 · External reference

Efficacy and toxicity of docetaxel combination chemotherapy for advanced squamous cell cancer of the head and neck

10.3892/mco.2017.1281 · 2017 · External reference

Cisplatin and fluorouracil induction chemotherapy with or without docetaxel in locoregionally advanced nasopharyngeal carcinoma

10.1016/j.tranon.2019.01.002 · 2019 · External reference

Docetaxel in the treatment of squamous cell carcinoma of the head and neck

2008 · External reference

Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein

10.1021/jm300207s · 2012 · External reference

Lysine demethylase 5B (KDM5B): a key regulator of cancer drug resistance

10.1002/jbt.23587 · 2023 · External reference

Precision medicine: ray of hope in overcoming cancer multidrug resistance

10.1016/j.drup.2022.100889 · 2022 · External reference

Third-generation tyrosine kinase inhibitors targeting epidermal growth factor receptor mutations in non-small cell lung cancer

10.3389/fonc.2017.00113 · 2017 · External reference

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor Cetuximab

10.1158/0008-5472.can-07-5659 · 2008 · External reference

Mechanisms of acquired resistance to AZD9291

10.1097/jto.0000000000000688 · 2015 · External reference

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR–MET interaction and activation of MET signaling in colon cancer cells

10.1158/1078-0432.ccr-13-0423 · 2013 · External reference

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

10.1038/ncomms13665 · 2016 · External reference

Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylase inhibitors in breast cancer

10.1016/j.ccell.2016.08.001 · 2016 · External reference

Tetracycline encapsulated in au nanoparticle-decorated ZnO Nanohybrids for enhanced antibacterial activity

10.1021/acsanm.2c00655 · 2022 · External reference

RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy

10.1016/j.jconrel.2021.10.028 · 2021 · External reference

Transcriptome-wide noise controls lineage choice in mammalian progenitor cells

10.1038/nature06965 · 2008 · External reference

Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies

10.1016/j.drup.2011.08.001 · 2011 · External reference

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance

10.1016/j.drup.2022.100821 · 2022 · External reference

Discovery of a novel 1H-pyrazole- [3,4-b] pyridine-based lysine demethylase 5B inhibitor with potential anti-prostate cancer activity that perturbs the phosphoinositide 3-kinase/AKT pathway

10.1016/j.ejmech.2023.115250 · 2023 · External reference

A KDM5 inhibitor increases global H3K4 Trimethylation occupancy and enhances the biological efficacy of 5-Aza-2′-deoxycytidine

10.1158/0008-5472.can-17-1453 · 2018 · External reference

Research progress of lysine specific Demethylase 1 in carcinoma

2015 · External reference

Structural definitions of Jumonji family demethylase selectivity

10.1016/j.drudis.2014.12.013 · 2015 · External reference

RBP2 belongs to a family of demethylases, specific for tri-and Dimethylated lysine 4 on histone 3

10.1016/j.cell.2007.02.003 · 2007 · External reference

PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation

10.1016/j.molcel.2007.03.001 · 2007 · External reference

The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases

10.1016/j.cell.2007.02.017 · 2007 · External reference

The PHD1 finger of KDM5B recognizes unmodified H3K4 during the demethylation of histone H3K4me2/3 by KDM5B

10.1007/s13238-014-0078-4 · 2014 · External reference

Characterization of a linked Jumonji domain of the KDM5/JARID1 family of histone H3 lysine 4 demethylases

10.1074/jbc.m115.698449 · 2016 · External reference

DNA-binding properties of ARID family proteins

2005 · External reference

JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer

10.1073/pnas.0700735104 · 2007 · External reference

Structural analysis of human KDM5B guides histone demethylase inhibitor development

10.1038/nchembio.2087 · 2026 · External reference

The PHD finger: a versatile epigenome reader

10.1016/j.tibs.2011.03.005 · 2011 · External reference

Targeting KDM5 demethylases: inhibition and degradation

10.2174/156802662004200304124340 · 2020 · External reference

LSD1/KDM1A inhibitors in clinical trials: advances and prospects

10.1186/s13045-019-0811-9 · 2019 · External reference

Structure and mechanism of lysine-specific demethylase enzymes

10.1074/jbc.r700027200 · 2007 · External reference

Targeting histone demethylases: a new avenue for the fight against cancer

10.1177/1947601911417976 · 2011 · External reference

Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells

10.1007/s10549-011-1480-8 · 2011 · External reference

Targeting histone demethylases: a new avenue for the fight against Cancer

10.1177/1947601911417976 · 2011 · External reference

The KDM5 family of histone demethylases as targets in oncology drug discovery

10.2217/epi.14.14 · 2014 · External reference

Molecular mechanisms of cisplatin resistance

10.1038/onc.2011.384 · 2012 · External reference

XRCC1-mediated repair of strand breaks independent of PNKP binding

10.1016/j.dnarep.2017.10.007 · 2017 · External reference

Effect of 5-fluorouracil on excision repair cross-complementing 1 expression and consequent cytotoxicity regulation in human gastric cancer cells

10.1002/jcb.27073 · 2018 · External reference

XRCC1 is a promising predictive biomarker and facilitates chemo-resistance in gallbladder cancer

10.3389/fmolb.2020.00070 · 2020 · External reference

TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer

10.1038/cddis.2014.27 · 2014 · External reference

KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance

10.7150/ijbs.25881 · 2018 · External reference

Identification of key genes and pathways in pancreatic cancer gene expression profile by integrative analysis

10.3390/genes10080612 · 2019 · External reference

Targeting TOP2A in ovarian cancer: biological and clinical implications

10.3390/curroncol31120594 · 2024 · External reference

Cell cycle-dependent control and roles of DNA topoisomerase II

10.3390/genes10110859 · 2019 · External reference

Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22

10.1073/pnas.85.19.7177 · 1988 · External reference

Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis

10.1038/s41418-024-01257-x · 2024 · External reference

KDM5A and KDM5B histone-demethylases contribute to HU-induced replication stress response and tolerance

10.1242/bio.057729 · 2021 · External reference

Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies

10.1038/onc.2014.155 · 2015 · External reference

Targeting the ATR-CHK1 axis in cancer therapy

10.3390/cancers9050041 · 2017 · External reference

Roles of Chk1 in cell biology and cancer therapy

10.1002/ijc.28226 · 2014 · External reference

Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1alpha, in a phase I clinical trial in patients with relapsed/refractory breast cancer

10.1006/bcmd.1998.0167 · 1998 · External reference

Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations

1988 · External reference

Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea

10.1038/sj.leu.2403006 · 2003 · External reference

Reversion of hydroxyurea resistance, decline in ribonucleotide reductase activity, and loss of M2 gene amplification

10.1016/0006-291x(87)91575-0 · 1987 · External reference

EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells

10.7150/thno.48101 · 2021 · External reference

MSC-induced lncRNA HCP5 drove fatty acid oxidation through miR-3619-5p/AMPK/PGC1α/CEBPB axis to promote stemness and chemo-resistance of gastric cancer

10.1038/s41419-020-2426-z · 2020 · External reference

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells

10.1038/cddis.2017.406 · 2017 · External reference

Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells

2018 · External reference

PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

10.1038/nature24040 · 2017 · External reference

The AhR-SRC axis as a therapeutic vulnerability in BRAFi-resistant melanoma

10.15252/emmm.202215677 · 2022 · External reference

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma

10.1038/sj.onc.1209379 · 2006 · External reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

10.1056/nejmoa1112302 · 2012 · External reference

Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors

10.1158/0008-5472.can-16-1755 · 2017 · External reference

KDM5B promotes drug resistance by regulating melanoma-propagating cell subpopulations

10.1158/1535-7163.mct-18-0395 · 2019 · External reference

LncRNA SNHG7 regulates mesenchymal stem cell through the Notch1/Jagged1/Hes-1 signaling pathway and influences Folfirinox resistance in pancreatic cancer

10.3389/fonc.2021.719855 · 2021 · External reference

Bone marrow mesenchymal stem cells promote prostate cancer cell stemness via cell-cell contact to activate the Jagged1/Notch1 pathway

10.1186/s13578-021-00599-0 · 2021 · External reference

Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance

10.3324/haematol.2019.221077 · 2020 · External reference

NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells

10.1074/jbc.ra118.006983 · 2019 · External reference

Prognostic significance of intra-tumoral budding in high-grade serous ovarian carcinomas

10.1038/s41598-022-07269-2 · 2022 · External reference

Notch signaling regulates mitochondrial metabolism and NF-κB activity in triple-negative breast cancer cells via IKKα-dependent non-canonical pathways

10.3389/fonc.2018.00575 · 2018 · External reference

Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

10.1038/s41419-024-06512-0 · 2024 · External reference

Inhibition of HER2 increases JAGGED1-dependent breast cancer stem cells: role for membrane JAGGED1

10.1158/1078-0432.ccr-17-1952 · 2018 · External reference

Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer

10.1111/jcmm.14286 · 2019 · External reference

Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop

10.18632/oncotarget.3241 · 2015 · External reference

TGFβ1-Smad3-Jagged1-Notch1-slug signaling pathway takes part in tumorigenesis and progress of tongue squamous cell carcinoma

10.1111/jop.12406 · 2016 · External reference

JARID1B expression plays a critical role in chemoresistance and stem cell-like phenotype of neuroblastoma cells

2015 · External reference

UPP1 enhances bladder cancer progression and gemcitabine resistance through AKT

10.7150/ijbs.83774 · 2024 · External reference

The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance

10.1038/s41467-018-07188-9 · 2018 · External reference

Endoplasmic reticulum (ER) stress induces Sirtuin 1 (SIRT1) expression via the PI3K-Akt-GSK3β signaling pathway and promotes hepatocellular injury

10.1074/jbc.m115.664169 · 2015 · External reference

Mucin 4 confers gemcitabine resistance and an unfavorable prognosis in patients with cholangiocarcinoma via AKT activation

10.7150/ijbs.79126 · 2023 · External reference

DNA damage and the balance between survival and death in cancer biology

10.1038/nrc.2015.2 · 2016 · External reference

TRIB1 confers therapeutic resistance in GBM cells by activating the ERK and Akt pathways

10.1038/s41598-023-32983-w · 2023 · External reference

Aurora-a induces chemoresistance through activation of the AKT/mTOR pathway in endometrial cancer

10.3389/fonc.2019.00422 · 2019 · External reference

Folic acid-modified Milk exosomes delivering c-kit siRNA overcome EGFR-TKIs resistance in lung cancer by suppressing mTOR signaling and stemness

10.7150/ijbs.99954 · 2025 · External reference

Overcoming cancer drug resistance with nanoparticle strategies for key protein inhibition

10.3390/molecules29173994 · 2024 · External reference

KDM5B predicts temozolomide-resistant subclones in glioblastoma

10.1016/j.isci.2023.108596 · 2024 · External reference

Potential strategies overcoming the Temozolomide resistance for glioblastoma

10.2176/nmc.ra.2018-0141 · 2018 · External reference

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011

10.1093/neuonc/nou223 · 2014 · External reference

Glioblastoma

10.1016/b978-0-12-802997-8.00023-2 · 2016 · External reference

TRIM31 enhances chemoresistance in glioblastoma through activation of the PI3K/Akt signaling pathway

10.3892/etm.2020.8782 · 2020 · External reference

SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis

10.1515/med-2020-0157 · 2020 · External reference

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

10.1007/s10555-016-9637-x · 2016 · External reference

Regulation of ferroptosis by PI3K/Akt signaling pathway: a promising therapeutic axis in cancer

10.3389/fcell.2024.1372330 · 2024 · External reference

Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)

10.1111/1759-7714.13328 · 2020 · External reference

LncRNA NONHSAT227443.1 confers esophageal squamous cell carcinoma chemotherapy resistance by activating PI3K/AKT signaling via targeting MRTFB

10.1177/15330338241274369 · 2024 · External reference

RNF149 confers cisplatin resistance in esophageal squamous cell carcinoma via destabilization of PHLPP2 and activating PI3K/AKT signalling

10.1007/s12032-023-02137-z · 2023 · External reference

MiR-124 regulates liver cancer stem cells expansion and sorafenib resistance

10.1016/j.yexcr.2020.112162 · 2020 · External reference

Targeting Jak/stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma

10.1016/j.jhep.2019.08.035 · 2020 · External reference

KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma

10.1097/cad.0000000000001329 · 2022 · External reference

KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid accumulation in pancreatic ductal adenocarcinoma

10.1038/s41420-024-02020-4 · 2024 · External reference

Pancreatic cancer

10.1038/nrdp.2016.22 · 2016 · External reference

Pancreatic cancer

10.1016/s0140-6736(10)62307-0 · 2011 · External reference

NFAT5 governs cellular plasticity-driven resistance to KRAS-targeted therapy in pancreatic cancer

10.1084/jem.20240766 · 2024 · External reference

SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy

10.1038/s41388-021-01726-4 · 2021 · External reference

TGFbeta prevents proteasomal degradation of the cyclin-dependent kinase inhibitor p27kip1 for cell cycle arrest

10.4161/cc.8.5.7871 · 2009 · External reference

Cancer immunotherapy via targeted TGF-β signalling blockade in T(H) cells

10.1038/s41586-020-2850-3 · 2020 · External reference

DPC4 gene in various tumor types

1996 · External reference

Whole genomes redefine the mutational landscape of pancreatic cancer

10.1038/nature14169 · 2015 · External reference

SMAD4 limits PARP1 dependent DNA repair to render pancreatic cancer cells sensitive to radiotherapy

10.1038/s41419-024-07210-7 · 2024 · External reference

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas

10.1016/j.bbcan.2024.189220 · 2024 · External reference

KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation

10.1186/gb-2014-15-2-r32 · 2014 · External reference

KDM5B regulates embryonic stem cell self-renewal and represses cryptic intragenic transcription

10.1038/emboj.2011.91 · 2011 · External reference

An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells

10.1038/nchembio.2085 · 2016 · External reference

Structural analysis of human KDM5B guides histone demethylase inhibitor development

10.1038/nchembio.2087 · 2016 · External reference

Structural basis for KDM5A histone lysine demethylase inhibition by diverse compounds

10.1016/j.chembiol.2016.06.006 · 2016 · External reference

KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance

10.1016/j.ccell.2018.10.014 · 2018 · External reference

A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

10.1016/j.cell.2010.02.027 · 2010 · External reference

Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma

10.1016/j.cell.2017.01.010 · 2017 · External reference

The blockade of immune checkpoints in cancer immunotherapy

10.1038/nrc3239 · 2012 · External reference

Cancer immunotherapy using checkpoint blockade

10.1126/science.aar4060 · 2018 · External reference

Primary, adaptive, and acquired resistance to cancer immunotherapy

10.1016/j.cell.2017.01.017 · 2017 · External reference

Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity

10.1016/j.celrep.2015.04.031 · 2015 · External reference

STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors

10.1016/j.immuni.2014.10.017 · 2014 · External reference

STING-mediated DNA sensing promotes antitumor and autoimmune responses to dying cells

10.4049/jimmunol.1401869 · 2014 · External reference

KDM5 histone demethylases repress immune response via suppression of STING

10.1371/journal.pbio.2006134 · 2018 · External reference

KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements

10.1038/s41586-021-03994-2 · 2021 · External reference

Innate immune pattern recognition: a cell biological perspective

10.1146/annurev-immunol-032414-112240 · 2015 · External reference

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

10.1038/nature07317 · 2008 · External reference

Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway

10.1126/science.1232458 · 2013 · External reference

Mitochondrial DNA stress primes the antiviral innate immune response

10.1038/nature14156 · 2015 · External reference